Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Alterations of RNA Metabolism by Proteomic Analysis of Breast Cancer Cells Exposed to Marycin: A New Optically Active Porphyrin.

Taverna E, De Bortoli M, Maffioli E, Corno C, Ciusani E, Trivulzio S, Pinelli A, Tedeschi G, Perego P, Bongarzone I.

Curr Mol Pharmacol. 2019;12(2):147-159. doi: 10.2174/1874467212666190204102112.

PMID:
30714537
2.

Lipid accumulation in human breast cancer cells injured by iron depletors.

De Bortoli M, Taverna E, Maffioli E, Casalini P, Crisafi F, Kumar V, Caccia C, Polli D, Tedeschi G, Bongarzone I.

J Exp Clin Cancer Res. 2018 Apr 3;37(1):75. doi: 10.1186/s13046-018-0737-z.

3.

Toward the Standardization of Mitochondrial Proteomics: The Italian Mitochondrial Human Proteome Project Initiative.

Alberio T, Pieroni L, Ronci M, Banfi C, Bongarzone I, Bottoni P, Brioschi M, Caterino M, Chinello C, Cormio A, Cozzolino F, Cunsolo V, Fontana S, Garavaglia B, Giusti L, Greco V, Lucacchini A, Maffioli E, Magni F, Monteleone F, Monti M, Monti V, Musicco C, Petrosillo G, Porcelli V, Saletti R, Scatena R, Soggiu A, Tedeschi G, Zilocchi M, Roncada P, Urbani A, Fasano M.

J Proteome Res. 2017 Dec 1;16(12):4319-4329. doi: 10.1021/acs.jproteome.7b00350. Epub 2017 Sep 13.

PMID:
28828861
4.

Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread.

Spreafico F, Bongarzone I, Pizzamiglio S, Magni R, Taverna E, De Bortoli M, Ciniselli CM, Barzanò E, Biassoni V, Luchini A, Liotta LA, Zhou W, Signore M, Verderio P, Massimino M.

Oncotarget. 2017 Jul 11;8(28):46177-46190. doi: 10.18632/oncotarget.17579.

5.

Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis.

Gloghini A, Volpi CC, Gualeni AV, Dolcetti R, Bongarzone I, De Paoli P, Carbone A.

Expert Rev Hematol. 2017 Jun;10(6):505-514. doi: 10.1080/17474086.2017.1326815. Epub 2017 May 16. Review.

PMID:
28468596
6.

Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors.

Pizzamiglio S, De Bortoli M, Taverna E, Signore M, Veneroni S, Cho WC, Orlandi R, Verderio P, Bongarzone I.

Int J Mol Sci. 2017 Feb 14;18(2). pii: E410. doi: 10.3390/ijms18020410.

7.

MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.

Bozzi F, Mogavero A, Varinelli L, Belfiore A, Manenti G, Caccia C, Volpi CC, Beznoussenko GV, Milione M, Leoni V, Gloghini A, Mironov AA, Leo E, Pilotti S, Pierotti MA, Bongarzone I, Gariboldi M.

J Exp Clin Cancer Res. 2017 Jan 23;36(1):16. doi: 10.1186/s13046-016-0475-z.

8.

Applicability of Under Vacuum Fresh Tissue Sealing and Cooling to Omics Analysis of Tumor Tissues.

Veneroni S, Dugo M, Daidone MG, Iorio E, Valeri B, Pinciroli P, De Bortoli M, Marchesi E, Miodini P, Taverna E, Ricci A, Canevari S, Pelosi G, Bongarzone I.

Biopreserv Biobank. 2016 Dec;14(6):480-490. Epub 2016 Jul 12.

PMID:
27403896
9.

Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone.

Ciniselli CM, De Bortoli M, Taverna E, Varinelli L, Pizzamiglio S, Veneroni S, Bonini C, Orlandi R, Verderio P, Bongarzone I.

Expert Rev Proteomics. 2015;12(6):695-701. doi: 10.1586/14789450.2015.1099436. Epub 2015 Oct 23.

PMID:
26496240
10.

Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer.

Lococo F, Paci M, Rapicetta C, Rossi T, Sancisi V, Braglia L, Cavuto S, Bisagni A, Bongarzone I, Noonan DM, Albini A, Maramotti S.

Int J Mol Sci. 2015 Aug 19;16(8):19612-30. doi: 10.3390/ijms160819612.

11.

4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.

Varinelli L, Caccia D, Volpi CC, Caccia C, De Bortoli M, Taverna E, Gualeni AV, Leoni V, Gloghini A, Manenti G, Bongarzone I.

Endocr Relat Cancer. 2015 Oct;22(5):759-75. doi: 10.1530/ERC-15-0299. Epub 2015 Jul 23.

PMID:
26206776
12.

Cell-secreted signals shape lymphoma identity.

Gloghini A, Bongarzone I.

Semin Cancer Biol. 2015 Oct;34:81-91. doi: 10.1016/j.semcancer.2015.02.001. Epub 2015 Mar 30. Review.

PMID:
25837156
13.

Molecular characterization of LASP-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells.

Salvi A, Bongarzone I, Ferrari L, Abeni E, Arici B, De Bortoli M, Scuri S, Bonini D, Grossi I, Benetti A, Baiocchi G, Portolani N, De Petro G.

Int J Oncol. 2015 May;46(5):1901-12. doi: 10.3892/ijo.2015.2923. Epub 2015 Mar 9.

14.

Stratification of clear cell renal cell carcinoma by signaling pathway analysis.

Cremona M, Espina V, Caccia D, Veneroni S, Colecchia M, Pierobon M, Deng J, Mueller C, Procopio G, Lanzi C, Daidone MG, Cho WC, Petricoin EF, Liotta L, Bongarzone I.

Expert Rev Proteomics. 2014 Apr;11(2):237-49. doi: 10.1586/14789450.2014.893193. Epub 2014 Feb 27.

PMID:
24575852
15.

Primary effusion lymphoma: secretome analysis reveals novel candidate biomarkers with potential pathogenetic significance.

Gloghini A, Volpi CC, Caccia D, Gualeni AV, Cilia AM, Carbone A, Bongarzone I.

Am J Pathol. 2014 Mar;184(3):618-30. doi: 10.1016/j.ajpath.2013.11.028. Epub 2014 Feb 10.

PMID:
24521760
16.

Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer.

Orlandi R, De Bortoli M, Ciniselli CM, Vaghi E, Caccia D, Garrisi V, Pizzamiglio S, Veneroni S, Bonini C, Agresti R, Daidone MG, Morelli D, Camaschella C, Verderio P, Bongarzone I.

Ann Oncol. 2014 Feb;25(2):352-7. doi: 10.1093/annonc/mdt490. Epub 2013 Dec 3.

PMID:
24306042
17.

Is Wilms tumor a candidate neoplasia for treatment with WNT/β-catenin pathway modulators?--A report from the renal tumors biology-driven drug development workshop.

Perotti D, Hohenstein P, Bongarzone I, Maschietto M, Weeks M, Radice P, Pritchard-Jones K.

Mol Cancer Ther. 2013 Dec;12(12):2619-27. doi: 10.1158/1535-7163.MCT-13-0335. Epub 2013 Nov 20. Review.

18.

Extracavitary KSHV-positive solid lymphoma: a large B-cell lymphoma within the spectrum of primary effusion lymphoma.

Carbone A, Volpi CC, Caccia D, Gualeni AV, Cilia AM, Bongarzone I, Gloghini A.

Am J Surg Pathol. 2013 Sep;37(9):1460-1. doi: 10.1097/PAS.0b013e31829caada. No abstract available.

19.

Bioinformatics tools for secretome analysis.

Caccia D, Dugo M, Callari M, Bongarzone I.

Biochim Biophys Acta. 2013 Nov;1834(11):2442-53. doi: 10.1016/j.bbapap.2013.01.039. Epub 2013 Feb 5. Review.

PMID:
23395702
20.

Body mass index and serum proteomic profile in breast cancer and healthy women: a prospective study.

Garrisi VM, Tufaro A, Trerotoli P, Bongarzone I, Quaranta M, Ventrella V, Tommasi S, Giannelli G, Paradiso A.

PLoS One. 2012;7(11):e49631. doi: 10.1371/journal.pone.0049631. Epub 2012 Nov 30.

21.

Proteomic profile in familial breast cancer patients.

Garrisi VM, Tommasi S, Facchiano A, Bongarzone I, De Bortoli M, Cremona M, Cafagna V, Abbate I, Tufaro A, Quaranta M, Paradiso A.

Clin Biochem. 2013 Feb;46(3):259-65. doi: 10.1016/j.clinbiochem.2012.11.003. Epub 2012 Nov 13.

PMID:
23159292
22.

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, Bongarzone I, Rodolfo M.

Neoplasia. 2011 Dec;13(12):1132-42.

23.

Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood.

Maramotti S, Paci M, Miccichè F, Ciarrocchi A, Cavazza A, De Bortoli M, Vaghi E, Formisano D, Canovi L, Sgarbi G, Bongarzone I.

Lung Cancer. 2012 Jun;76(3):332-8. doi: 10.1016/j.lungcan.2011.11.018. Epub 2011 Dec 15.

PMID:
22177532
24.

Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.

Da Riva L, Bozzi F, Mondellini P, Miccichè F, Fumagalli E, Vaghi E, Tarantino E, Huber V, Gronchi A, Tamborini E, Pierotti MA, Pilotti S, Bongarzone I.

J Transl Med. 2011 Sep 23;9:158. doi: 10.1186/1479-5876-9-158.

25.

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target.

Zappasodi R, Bongarzone I, Ghedini GC, Castagnoli L, Cabras AD, Messina A, Tortoreto M, Tripodo C, Magni M, Carlo-Stella C, Gianni AM, Pupa SM, Di Nicola M.

Blood. 2011 Oct 20;118(16):4421-30. doi: 10.1182/blood-2011-06-364570. Epub 2011 Aug 22.

PMID:
21860023
26.

Secretome compartment is a valuable source of biomarkers for cancer-relevant pathways.

Caccia D, Zanetti Domingues L, Miccichè F, De Bortoli M, Carniti C, Mondellini P, Bongarzone I.

J Proteome Res. 2011 Sep 2;10(9):4196-207. doi: 10.1021/pr200344n. Epub 2011 Jul 29.

PMID:
21751813
27.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
28.

Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.

Borrello MG, Aiello A, Peissel B, Rizzetti MG, Mondellini P, Degl'Innocenti D, Catalano V, Gobbo M, Collini P, Bongarzone I, Pierotti MA, Greco A, Seregni E.

Endocr Relat Cancer. 2011 Jul 25;18(4):519-27. doi: 10.1530/ERC-10-0306. Print 2011 Aug.

PMID:
21690267
29.

Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib.

Garrisi VM, Bongarzone I, Mangia A, Cremona M, De Bortoli M, Vaghi E, Galetta D, Pastorino U, Quaranta M, Abbate I, Paradiso A.

Clin Biochem. 2011 Jul;44(10-11):936-40. doi: 10.1016/j.clinbiochem.2011.04.013. Epub 2011 Apr 22.

PMID:
21539823
30.

Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors.

Miccichè F, Da Riva L, Fabbi M, Pilotti S, Mondellini P, Ferrini S, Canevari S, Pierotti MA, Bongarzone I.

PLoS One. 2011 Feb 22;6(2):e17141. doi: 10.1371/journal.pone.0017141.

31.

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Caccia D, Miccichè F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I.

Mol Cancer. 2010 Oct 18;9:278. doi: 10.1186/1476-4598-9-278.

32.

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, Colombo MP, Carlo-Stella C, Gianni AM, Di Nicola M.

Cancer Res. 2010 Nov 15;70(22):9062-72. doi: 10.1158/0008-5472.CAN-10-1825. Epub 2010 Sep 30.

33.

Proteome profile in Myotonic Dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways.

Rusconi F, Mancinelli E, Colombo G, Cardani R, Da Riva L, Bongarzone I, Meola G, Zippel R.

Neurobiol Dis. 2010 May;38(2):273-80. doi: 10.1016/j.nbd.2010.01.017. Epub 2010 Feb 4.

PMID:
20138216
34.

Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk.

Cremona M, Calabrò E, Randi G, De Bortoli M, Mondellini P, Verri C, Sozzi G, Pierotti MA, La Vecchia C, Pastorino U, Bongarzone I.

Cancer. 2010 Mar 1;116(5):1326-35. doi: 10.1002/cncr.24868.

35.

Impact of biospecimens handling on biomarker research in breast cancer.

De Cecco L, Musella V, Veneroni S, Cappelletti V, Bongarzone I, Callari M, Valeri B, Pierotti MA, Daidone MG.

BMC Cancer. 2009 Nov 24;9:409. doi: 10.1186/1471-2407-9-409.

36.

Thyroid iatrogenic sequelae after the treatment of pediatric cancer.

Massimino M, Gandola L, Seregni E, Bongarzone I, Morosi C, Collini P.

Q J Nucl Med Mol Imaging. 2009 Oct;53(5):526-35. Review.

37.

Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells.

Salvi A, Bongarzone I, Miccichè F, Arici B, Barlati S, De Petro G.

Neoplasia. 2009 Feb;11(2):207-19.

38.

Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.

Gorla L, Mondellini P, Cuccuru G, Miccichè F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C, Bongarzone I.

Mol Carcinog. 2009 Mar;48(3):220-231. doi: 10.1002/mc.20474.

PMID:
18756447
39.

The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.

Rosso O, Piazza T, Bongarzone I, Rossello A, Mezzanzanica D, Canevari S, Orengo AM, Puppo A, Ferrini S, Fabbi M.

Mol Cancer Res. 2007 Dec;5(12):1246-53. doi: 10.1158/1541-7786.MCR-07-0060.

40.

Regulation of breast cancer response to chemotherapy by fibulin-1.

Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I, Baldassari P, Mortarini R, Argraves WS, Anichini A, Menard S, Tagliabue E.

Cancer Res. 2007 May 1;67(9):4271-7.

41.

SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling.

Donatello S, Fiorino A, Degl'Innocenti D, Alberti L, Miranda C, Gorla L, Bongarzone I, Rizzetti MG, Pierotti MA, Borrello MG.

Oncogene. 2007 Oct 4;26(45):6546-59. Epub 2007 Apr 30.

PMID:
17471236
42.

RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.

Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellini P, Leyland J, Pierotti MA, Whittaker J, Taylor SS, Bongarzone I, Ponder BA.

Cancer Res. 2006 Oct 15;66(20):10179-87.

43.

RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism.

Gorla L, Cantù M, Miccichè F, Patelli C, Mondellini P, Pierotti MA, Bongarzone I.

Cell Signal. 2006 Dec;18(12):2272-82. Epub 2006 May 24.

PMID:
16843637
44.

Molecular predictors of response and outcome in ovarian cancer.

Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA.

Crit Rev Oncol Hematol. 2006 Oct;60(1):19-37. Epub 2006 Jul 7. Review.

PMID:
16829123
45.

The Ret(C620R) mutation affects renal and enteric development in a mouse model of Hirschsprung's disease.

Carniti C, Belluco S, Riccardi E, Cranston AN, Mondellini P, Ponder BA, Scanziani E, Pierotti MA, Bongarzone I.

Am J Pathol. 2006 Apr;168(4):1262-75.

46.

A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation.

Cranston A, Carniti C, Martin S, Mondellini P, Hooks Y, Leyland J, Hodgson S, Clarke S, Pierotti M, Ponder BA, Bongarzone I.

Mol Endocrinol. 2006 Jul;20(7):1633-43. Epub 2006 Feb 9.

PMID:
16469774
47.

90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.

Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, Bombardieri E, Martin F, Giussani A, Figini M, Canevari S.

Cancer Immunol Immunother. 2005 Dec;54(12):1200-13. Epub 2005 May 31.

PMID:
15926078
48.

Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody.

Piazza T, Cha E, Bongarzone I, Canevari S, Bolognesi A, Polito L, Bargellesi A, Sassi F, Ferrini S, Fabbi M.

J Cell Sci. 2005 Apr 1;118(Pt 7):1515-25. Epub 2005 Mar 15.

49.

Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.

Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A.

Oncogene. 2004 Sep 23;23(44):7436-40.

PMID:
15273715
50.

RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor.

Bongarzone I, Carniti C, Perego C, Mondellini P, Pierotti MA.

Tumori. 2003 Sep-Oct;89(5):550-2. Review.

PMID:
14870784

Supplemental Content

Loading ...
Support Center